IRIS
Del Re, Marzia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.298
NA - Nord America 2.057
SA - Sud America 777
EU - Europa 408
AF - Africa 107
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.652
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.875
SG - Singapore 729
BR - Brasile 591
CN - Cina 415
BD - Bangladesh 328
HK - Hong Kong 312
IT - Italia 248
VN - Vietnam 153
MX - Messico 99
IN - India 81
AR - Argentina 61
IQ - Iraq 54
CA - Canada 48
CO - Colombia 41
TR - Turchia 38
EC - Ecuador 29
ID - Indonesia 29
SA - Arabia Saudita 27
RU - Federazione Russa 26
ZA - Sudafrica 24
PK - Pakistan 23
VE - Venezuela 23
GB - Regno Unito 22
PH - Filippine 19
FR - Francia 17
MA - Marocco 15
NL - Olanda 15
UZ - Uzbekistan 14
UA - Ucraina 13
ES - Italia 12
MY - Malesia 12
DE - Germania 11
TN - Tunisia 11
DZ - Algeria 10
CR - Costa Rica 9
JO - Giordania 9
KE - Kenya 9
PY - Paraguay 9
EG - Egitto 8
JM - Giamaica 8
BO - Bolivia 7
AZ - Azerbaigian 6
CL - Cile 6
PS - Palestinian Territory 6
RS - Serbia 6
TT - Trinidad e Tobago 6
KZ - Kazakistan 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AO - Angola 4
HN - Honduras 4
HU - Ungheria 4
IE - Irlanda 4
IR - Iran 4
LB - Libano 4
NG - Nigeria 4
NP - Nepal 4
PE - Perù 4
ET - Etiopia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
TH - Thailandia 3
ZW - Zimbabwe 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
CG - Congo 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
FI - Finlandia 2
GE - Georgia 2
IL - Israele 2
KR - Corea 2
LT - Lituania 2
MU - Mauritius 2
PL - Polonia 2
RO - Romania 2
SN - Senegal 2
UG - Uganda 2
AM - Armenia 1
BB - Barbados 1
CH - Svizzera 1
CM - Camerun 1
CY - Cipro 1
GM - Gambi 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
JP - Giappone 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
MZ - Mozambico 1
Totale 5.637
Salva come PNG Salva come JPEG
Città #
San Jose 1.074
Singapore 422
Hong Kong 304
Ashburn 263
Beijing 204
Mexico City 81
Ho Chi Minh City 71
Santa Clara 64
Rome 59
New York 39
São Paulo 29
Hanoi 24
Milan 23
Los Angeles 22
Rio de Janeiro 22
Buffalo 16
Istanbul 15
Baghdad 13
Brasília 13
Lahore 13
Medellín 13
Caracas 12
Chicago 12
Curitiba 12
Tashkent 12
Council Bluffs 11
Dallas 11
Dhaka 11
Naples 11
Belo Horizonte 10
Jeddah 10
Orem 10
Quito 10
Ribeirão Preto 10
Amman 9
Bogotá 9
Haiphong 9
Nairobi 9
Guayaquil 8
Moscow 8
Riyadh 8
Campinas 7
Goiânia 7
Jakarta 7
San José 7
São José dos Campos 7
Tunis 7
Asunción 6
Atlanta 6
Baku 6
Charlotte 6
Da Nang 6
Erbil 6
Johannesburg 6
Karbala 6
London 6
Osasco 6
Salvador 6
Toronto 6
Bari 5
Belém 5
Biên Hòa 5
Bologna 5
Buenos Aires 5
Canoas 5
Cape Town 5
Catania 5
Fortaleza 5
Houston 5
Hyderabad 5
Kuala Lumpur 5
La Paz 5
Porto Alegre 5
Anápolis 4
Bauru 4
Belgrade 4
Cagliari 4
Casablanca 4
Ceres 4
Cleveland 4
Dammam 4
Feira de Santana 4
Guarulhos 4
Kirkuk 4
Lima 4
Manaus 4
Medina 4
Montevideo 4
Montreal 4
New Delhi 4
Niterói 4
Pelotas 4
Pune 4
Quezon City 4
Rabat 4
Rondonópolis 4
San Antonio 4
Taubaté 4
Turin 4
Vitória da Conquista 4
Totale 3.278
Salva come PNG Salva come JPEG
Nome #
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours 75
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 68
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 59
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients 58
Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma 55
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance 54
Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: A systematic review protocol 51
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 51
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 51
Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool 50
The Role of ctDNA for Diagnosis and Histological Prediction in Early Stage Non-Small-Cell Lung Cancer: A Narrative Review 49
Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation 48
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view 48
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 48
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 48
Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review 48
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 47
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 46
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 46
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 45
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 45
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 43
EGFR signaling pathway as therapeutic target in human cancers 43
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs 42
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences 41
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer 41
The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies 39
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 39
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series 38
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines 38
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 38
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives 37
β3-adREnoceptor Analysis in CORD Blood of Neonates (β3 RECORD): Study Protocol of a Pilot Clinical Investigation 37
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 37
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 36
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 36
ANKRd44 gene silencing: A putative role in trastuzumab resistance in HER2-like breast cancer 36
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 36
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis 35
Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data 35
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 34
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 34
Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years 34
Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors 34
Empower the potential of trastuzumab deruxtecan with novel combinations 34
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 34
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 33
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 33
Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA 33
Facing an un-met need in lung cancer screening: The never smokers 33
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 33
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment 33
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 33
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated Acute Myeloid Leukemia (AML) to guide treatment strategy 32
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 32
Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives 32
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice 32
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 31
The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma 31
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 31
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 31
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 31
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib 30
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA 30
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 30
Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments 30
Recommendations for using molecular assays on liquid biopsy: the first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC | Raccomandazioni per l’esecuzione di indagini molecolari su biopsia liquida in oncologia 30
A real-world application of liquid biopsy in metastatic colorectal cancer: The poseidon study 30
TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma 30
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 30
Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients 30
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes 30
Cross-Linked Hyaluronic Acid as Tear Film Substitute 30
Author's reply. Should CYP2D6 be genotyped when treating with tamoxifen? Pharmacogenomics 30
Recurrent USP6 rearrangement in a subset of atypical myofibroblastic tumours of the soft tissues: low-grade myofibroblastic sarcoma or atypical/malignant nodular fasciitis? 29
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report 29
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 29
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 29
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 29
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 29
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 29
Author's reply 29
Genome Wide Association Studies (GWAS) 29
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 29
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 29
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards 29
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 29
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) 29
Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project 29
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 29
Should CYP2D6 be genotyped when treating with tamoxifen? 29
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges 28
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 28
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 28
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics 28
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 28
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 28
Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors 28
Understanding EGFR heterogeneity in lung cancer 28
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 27
Totale 3.639
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.379
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.379
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.169 0 0 0 44 19 50 69 149 168 33 309 328
2025/20264.691 176 38 271 244 467 265 441 256 1.089 555 499 390
Totale 5.860